I-Mab (IMAB)
NASDAQ: IMAB · Real-Time Price · USD
0.9199
-0.0251 (-2.66%)
May 13, 2025, 4:00 PM - Market closed
I-Mab Employees
I-Mab had 32 employees as of December 31, 2024. The number of employees decreased by 188 or -85.45% compared to the previous year.
Employees
32
Change (1Y)
-188
Growth (1Y)
-85.45%
Revenue / Employee
n/a
Profits / Employee
-$694,688
Market Cap
74.97M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
IMAB News
- 7 weeks ago - I-Mab Announces Receipt Of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement - GlobeNewsWire
- 2 months ago - I-Mab Announces Accelerated Givastomig Phase 1b Study Progress - GlobeNewsWire
- 3 months ago - I-Mab to Participate in Leerink Partners Global Healthcare Conference - GlobeNewsWire
- 3 months ago - I-Mab to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 4 months ago - I-Mab Announces Open Market Purchases of Company American Depositary Shares by Board Member - PRNewsWire
- 4 months ago - I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program - PRNewsWire
- 6 months ago - I-Mab to Participate at the Piper Sandler Healthcare Conference - PRNewsWire
- 6 months ago - I-Mab Reports Third Quarter 2024 Results - PRNewsWire